Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. DOI: https://doi.org/10.3322/caac.21660

Li X, QiuM, Wang S, et al. A phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. Cancer Chemother Pharmacol 2020;85:593-604. DOI: https://doi.org/10.1007/s00280-020-04031-1

Bi F, Qiu M, Chai X, et al. A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2017;35(Suppl.):abstr e15682. DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.e15682

Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial. J Clin Oncol 2021;39:3002-11. DOI: https://doi.org/10.1200/JCO.21.00163

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. DOI: https://doi.org/10.1056/NEJMoa0708857

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. DOI: https://doi.org/10.1016/S0140-6736(18)30207-1

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-05. DOI: https://doi.org/10.1056/NEJMoa1915745

Porta C, Broglia C, Negri F. Medical treatment of advanced hepatocellular carcinoma patients: the issue is not the right drug, but the right patient. Hepatology 2019;70:429-30. DOI: https://doi.org/10.1002/hep.30521

Farrell GC, Haczeyni F, Chitturi S. Pathogenesis of NASH: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease. Adv Exp Med Biol 2018;1061:19-44. DOI: https://doi.org/10.1007/978-981-10-8684-7_3

Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188391. DOI: https://doi.org/10.1016/j.bbcan.2020.188391

Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289-00. DOI: https://doi.org/10.1056/NEJMoa2035716

Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2020;38:2960-70. DOI: https://doi.org/10.1200/JCO.20.00808